Between 15 March and 6 July 2021, 348 confirmed S. Braenderup sequence type 22 (ST22) cases were reported in 12 European Union/European Economic Area (EU/EEA) countries and the United Kingdom (UK).
Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
Between May 2018 and December 2020, 193 human cases of Salmonella Enteritidis sequence type (ST)11 were reported in Denmark (2), Finland (4), France (33), Germany (6), Ireland (12), the Netherlands (3), Poland (5), Sweden (6), and the United Kingdom (UK) (122). One in five cases was hospitalised. One death was reported. Fifty percent of the cases were children ≤ 18 years. The most recent case was reported by the UK in December 2020.
A multi-country outbreak of Salmonella enterica subspecies enterica serovar Agona (S. Agona) is under investigation in the European Union (EU), with cases retrospectively identified back to 2014.
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
This document provides an assessment of the public health risk associated with a multi-country outbreak of Salmonella Agona associated with consumption of potentially contaminated infant formula from France.
An outbreak of S. Enteritidis phage type 8 is ongoing in the EU/EEA. Isolates are part of two distinct but related genetic clusters. ECDC and EFSA are liaising with relevant authorities to facilitate the coordination of investigation response measures.
This rapid risk assessment assesses the recurrent multi-country outbreak of Salmonella Enteritidis due to a persistent source of infection, with current or recent exposure in at least four EU/EEA Member States.
The goal of this systematic review is to update the 2011 ECDC risk assessment. Evidence from this review will be used to develop guidance on this topic.
This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.